You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Drug Sales Trends for GEQ PRILOSEC


✉ Email this page to a colleague

« Back to Dashboard


Drug Sales Revenue Trends for GEQ PRILOSEC
Drug Units Sold Trends for GEQ PRILOSEC

Annual Sales Revenues and Units Sold for GEQ PRILOSEC

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
GEQ PRILOSEC ⤷  Try for Free ⤷  Try for Free 2022
GEQ PRILOSEC ⤷  Try for Free ⤷  Try for Free 2021
GEQ PRILOSEC ⤷  Try for Free ⤷  Try for Free 2020
GEQ PRILOSEC ⤷  Try for Free ⤷  Try for Free 2019
GEQ PRILOSEC ⤷  Try for Free ⤷  Try for Free 2018
>Drug Name >Revenues (USD) >Units >Year

Market Analysis and Sales Projections for Omeprazole (GEQ PriLOSEC)

Last updated: December 31, 2024

Introduction to Omeprazole

Omeprazole, commonly known by the brand name PriLOSEC, is a proton pump inhibitor (PPI) widely used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. Here’s a comprehensive analysis of the market and sales projections for omeprazole.

Market Size and Growth

The global market for omeprazole and other proton pump inhibitors is experiencing significant growth. As of 2023, the proton pump inhibitors market was valued at around USD 4.90 billion and is projected to reach USD 7.35 billion by 2031, growing at a CAGR of 5.2% during the forecast period[2][5].

Key Drivers of Market Growth

Increasing Prevalence of GERD and Other Gastrointestinal Conditions

The growing prevalence of GERD is a major driver of the omeprazole market. GERD affects approximately 20% of adults in Western societies, making it one of the most widespread gastrointestinal conditions[1].

Rising Demand for Over-the-Counter (OTC) Medications

Omeprazole is increasingly available as an OTC medication, which has boosted its demand. The convenience and affordability of OTC medications make them a preferred choice for many consumers, contributing to the market's growth[3].

Lifestyle Factors and Health Awareness

Changes in lifestyle, such as unhealthy eating habits and poor sleep cycles, are contributing to the rise in gastrointestinal issues. Increased awareness about the benefits of PPIs in managing these conditions is also driving the market[3].

Regional Market Analysis

North America

North America is expected to hold a significant share in the omeprazole market. The region's high prevalence of diseases like gastric ulcers and GERD, coupled with the launch of new products by key players, is driving market growth. The obesity index in the United States has increased significantly, from 30.5% in 1999-2000 to 41.9% in 2017-2022, further exacerbating gastro-related issues and boosting the demand for omeprazole[1][3].

Other Regions

Other regions, including Europe, Latin America, and Asia-Pacific, are also witnessing steady growth due to increasing health awareness and the rising incidence of chronic diseases. The global reach of omeprazole is extensive, with key market players operating across multiple regions[5].

Market Segmentation

By Drug Type

Omeprazole dominates the PPI market, capturing around 28.5% of the global market share in 2022. Other PPIs, such as lansoprazole and esomeprazole, also contribute to the market but to a lesser extent[5].

By Route of Administration

Omeprazole is available in various forms, including oral capsules, tablets, and intravenous formulations. The oral route is the most common, given its ease of administration and patient compliance[5].

By Prescription Type

Both prescription and OTC segments are driving the market. The OTC segment is particularly growing due to its convenience and accessibility[3].

By Distribution Channel

Hospital pharmacies, retail pharmacies, and drug stores are the primary distribution channels. Online pharmacies are also gaining traction, contributing to the market's expansion[5].

Challenges and Barriers

Side Effects

Despite its effectiveness, omeprazole can have side effects such as headaches, diarrhea, and abdominal pain. These side effects can pose a barrier to market expansion, especially if alternative treatments with fewer side effects become available[3].

Generic Competition

The entry of generic versions of omeprazole can reduce the market share of branded products. However, the demand for omeprazole remains high due to its established efficacy and patient trust[5].

Clinical Trials and Innovations

Recent clinical trials, such as those conducted by RedHill Biopharma on the Talicia capsule, which combines antibiotics and a PPI, have shown positive results in treating Helicobacter pylori infections. Such innovations are expected to further boost the demand for omeprazole and other PPIs[4].

Sales Projections

  • Short-term (2023 to 2026): The market is expected to see steady growth driven by the increasing popularity of OTC medications and the rising prevalence of GERD. The global omeprazole market is projected to grow at a CAGR of around 5-6% during this period[3][4].
  • Medium-term (2026 to 2029): The market will continue to grow due to the aging population and increasing gastro-related issues. The North American market, in particular, is expected to grow at a CAGR of 3.5% to reach USD 1,405.71 million by 2033[3].
  • Long-term (2029 to 2033): The market is anticipated to experience significant growth driven by increased research and development, leading to innovative solutions and higher awareness about the benefits of PPIs. The global omeprazole market is expected to reach USD 7.35 billion by 2031 and USD 2.56 billion by 2037, respectively[2][4].

Key Takeaways

  • The omeprazole market is driven by the increasing prevalence of GERD and other gastrointestinal conditions.
  • The demand for OTC medications is a significant factor in market growth.
  • North America is expected to hold a significant share in the market due to high disease prevalence and product launches.
  • Side effects and generic competition are potential barriers to market expansion.
  • Innovations in clinical trials and increasing health awareness will continue to drive the market.

FAQs

What is the current market size of the proton pump inhibitors market?

The proton pump inhibitors market was valued at around USD 4.90 billion in 2023[2].

What is the projected growth rate of the omeprazole market?

The omeprazole market is expected to grow at a CAGR of around 5-6% during the forecast period[3][4].

Which region is expected to hold a significant share in the omeprazole market?

North America is anticipated to hold a significant share in the omeprazole market due to the high prevalence of diseases like GERD and gastric ulcers[1].

What are the key drivers of the omeprazole market?

The key drivers include the increasing prevalence of GERD, rising demand for OTC medications, and lifestyle factors such as unhealthy eating habits and poor sleep cycles[1][3].

Are there any challenges to the growth of the omeprazole market?

Yes, side effects and generic competition are potential barriers to market expansion[3].

How is the market segmented?

The market is segmented by drug type, route of administration, dosage form, prescription type, indication, and distribution channel[5].

Sources

  1. Mordor Intelligence: Omeprazole And Antihistamine Market Size & Share Analysis
  2. GlobeNewswire: Proton Pump Inhibitors Market to Surpass Valuation of USD 7.35 Billion by 2031
  3. Fact.MR: Omeprazole Sulfone Market Size, Demand & Growth Analysis
  4. ResearchNester: Omeprazole Market Size & Share | Growth Forecasts 2037
  5. Future Market Insights: Proton Pump Inhibitors Market Share & Forecast by 2033

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.